AUSTIN, Texas, March 04, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that results of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback